admin

Phlow is strategically working with the U.S. government to ensure preparedness for future national health crises  

October 20, 2021 09:00 AM Eastern Daylight Time

RICHMOND, Va.–(BUSINESS WIRE)–Phlow Corp., a U.S.-based essential medicines impact company, today announced that it has been approved for inclusion in the Biomedical Advanced Research and Development Authority (BARDA) contract development and manufacturing organization (CDMO) network. The network is part of a comprehensive effort by the U.S. government to provide a domestically integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools to address public health emergencies.  

This Forbes special section showcases how the state continues to step up its game to keep businesses thriving. Maryland’s dynamic and ever-growing aerospace, cybersecurity, energy, financial services, life sciences, manufacturing, and real estate industries are all showcased throughout the publication.

Each year BioProcess International publishes over 150 articles focusing on the latest science, technologies, and techniques supporting biopharmaceutical research, development, and manufacturing. As publishers, we work closely with industry authors and our editorial advisory board members to select, edit, and review every article before publication to ensure that it meets the high standard you have come to expect from BPI.

The United States is on edge in ways the nation has rarely experienced throughout its young history. The country’s global leadership is being challenged in a rapidly changing and increasingly competitive world. Meanwhile, the nation’s sustained complacency in dealing with long-festering domestic needs has weakened our institutions from within and placed in grave danger our leadership in the critical fields of science and technology—on which so much of our economy and security is based. America is at a tipping point, in short, and Americans are justifiably unsettled.

Mr. Hakdo Kim, President, Korea SMEs & Startups Agency KOSME), joins Rich Bendis from the BHI Offices to discuss their biotech mission, their relationship with Maryland, and opportunities to expand in the United States

Listen now on Apple https://apple.co/2XGxg7i, Google https://bit.ly/3bbuDxz, Spotify https://spoti.fi/2XI5h7n, and TuneIn https://bit.ly/2XGwYNJ.

October 20, 2021    |   By Deborah Kotz

University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that UMSOM has been awarded $1.25 million in matching funds from the Maryland E-Nnovation Initiative Fund (MEIF), administered by the Maryland Department of Commerce. The funds, totaling $2.5 million when combined with private philanthropy, will enable the establishment of a new Center for Pathogen Research. They will also enable UMSOM to support research professorships in the Department of Microbiology and Immunology and the Department of Neurology.

The Alicia and Yaya Foundation made a $750,000 philanthropic commitment to establish the Alicia and Yaya Foundation Professorship in Pathogen Research in the Department of Microbiology and Immunology. Matching state funds bring the total to $1.5 million, which will establish an endowed professorship for Matthew Frieman, PhD, associate professor of Microbiology and Immunology at UMSOM. He will also serve as the director of a new Center for Pathogen Research.

Danae expands its 3-D Print manufacturing capacity, adds access to unique 3D printing technologies from Materic

October 21, 2021, Baltimore, MD – Danae, Inc., a Baltimore-based 3-D Printing design and manufacturing company, today announced it has partnered with Materic, LLC and received investment from Conscious Venture Partners through their Conscious Venture Fund II.

Located at Baltimore’s 1100 Wicomico, Danae has used this investment to install eight new printers to meet its rapidly growing customer demand. The new machines extend Danae’s capabilities allowing them to manufacture parts using Selective Laser Sintering (SLS) or Stereolithography (SLA) technologies. SLS uses a laser to transform powder into a 3D model whereas SLA uses a laser to cure liquid resin into hardened plastic.

GYEONGGI-DO, Korea & GAITHERSBURG, Md., October 19, 2021–(BUSINESS WIRE)–D&D Pharmatech Inc., a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, and parent company of U.S.-based Neuraly Inc., Precision Molecular, Inc., Theraly Fibrosis Inc., P4Microbiome and Valted Seq, today announced that it has completed a $51 million Series C round of financing led by Praxis Capital Partners, a private equity firm that focuses on growth acquisitions and investments in Asia; other investors included DS Asset Management, Kudos Ventures and Korea Investment & Securities. The new round of financing builds upon the $137.1 million the company secured in Series B financing in August 2019. The company is planning an initial public offering in Korea in 2022.